Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR⁺/HER2⁻ advanced breast cancer.
- 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- 2Beijing Key Laboratory of Breast Cancer Innovative Drug Development and Translational Research, Beijing 100021, China.
Abstract
The addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy has redefined the treatment paradigm for HR-positive, HER2-negative (HR⁺/HER2⁻) advanced breast cancer, with clear survival gains. However, resistance is almost inevitable and remains the central barrier to durable benefit. Selective estrogen receptor degraders (SERDs) have therefore moved from a later-line option to a core component of post-progression strategies aimed at targeting ESR1 mutations and estrogen receptor (ER) pathway reactivation. Notably, oral SERDs differ substantially in ER occupancy, degradation potency, and pharmacokinetic behavior, and these differences appear to translate into distinct efficacy and toxicity profiles across studies. This review summarizes recent progress in SERD-based therapeutic strategies, with a focus on post-CDK4/6 inhibitor sequencing and biomarker-driven combination approaches. Particular attention is given to rational combinations with PI3Kα and AKT inhibitors, HER2-directed tyrosine kinase inhibitors, and emerging targets such as FGFR, CDK2, and CDK7, as well as the growing role of liquid biopsy in guiding treatment adaptation. Together, these developments position SERD-centered strategies as a key framework for advancing mechanism-informed, precision treatment in HR⁺/HER2⁻ advanced breast cancer.
Related
- Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.
- CDK4/6 Inhibitors in the Treatment of Advanced ER/PR-Positive, HER2-Negative Breast Cancer: An Updated Single-Center Analysis of Real-World Data
- Immune checkpoint inhibitors combined with VEGF/VEGFR-targeted therapy in microsatellite-stable advanced colorectal cancer: clinical advances and the potential for immune-sensitive tumor conversion
- Synergizing Against RAS: The Evolving Landscape of Targeted Combinations in Pancreatic Cancer
- From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells
BibTeX
@article{wang2026post,
title = {{Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR⁺/HER2⁻ advanced breast cancer.}},
author = {Yan Wang and Jiayu Wang and Binghe Xu},
journal = {Acta pharmaceutica Sinica. B},
year = {2026},
month = jul,
doi = {10.1016/j.apsb.2026.07.050},
url = {https://europepmc.org/article/MED/42948694},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR⁺/HER2⁻ advanced breast cancer.
AU - Yan Wang
AU - Jiayu Wang
AU - Binghe Xu
PY - 2026
DA - 2026/07/31
JO - Acta pharmaceutica Sinica. B
DO - 10.1016/j.apsb.2026.07.050
UR - https://europepmc.org/article/MED/42948694
AB - The addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy has redefined the treatment paradigm for HR-positive, HER2-negative (HR⁺/HER2⁻) advanced breast cancer, with clear survival gains. However, resistance is almost inevitable and remains the central barrier to durable benefit. Selective estrogen receptor degraders (SERDs) have therefore moved from a later-line option to a core component of post-progression strategies aimed at targeting ESR1 mutations and estrogen receptor (ER) pathway reactivation. Notably, oral SERDs differ substantially in ER occupancy, degradation potency, and pharmacokinetic behavior, and these differences appear to translate into distinct efficacy and toxicity profiles across studies. This review summarizes recent progress in SERD-based therapeutic strategies, with a focus on post-CDK4/6 inhibitor sequencing and biomarker-driven combination approaches. Particular attention is given to rational combinations with PI3Kα and AKT inhibitors, HER2-directed tyrosine kinase inhibitors, and emerging targets such as FGFR, CDK2, and CDK7, as well as the growing role of liquid biopsy in guiding treatment adaptation. Together, these developments position SERD-centered strategies as a key framework for advancing mechanism-informed, precision treatment in HR⁺/HER2⁻ advanced breast cancer.
SN - 2211-3835
SN - 2211-3843
ER -